These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 2121738)
21. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin. Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385 [TBL] [Abstract][Full Text] [Related]
22. [Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine]. Kudoh K; Kita T; Hirata J; Ishii K; Hiramatsu H; Kikuchi Y; Nagata I Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jun; 46(6):525-32. PubMed ID: 8040625 [TBL] [Abstract][Full Text] [Related]
23. In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors. Frühauf S; Zeller WJ Cancer Chemother Pharmacol; 1991; 27(4):301-7. PubMed ID: 1998986 [TBL] [Abstract][Full Text] [Related]
25. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Chen G; Hutter KJ; Zeller WJ Cell Biol Toxicol; 1995 Oct; 11(5):273-81. PubMed ID: 8608408 [TBL] [Abstract][Full Text] [Related]
26. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Oldenburg J; Begg AC; van Vugt MJ; Ruevekamp M; Schornagel JH; Pinedo HM; Los G Cancer Res; 1994 Jan; 54(2):487-93. PubMed ID: 8275486 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo. Chen G; Zeller WJ Cancer Chemother Pharmacol; 1990; 26(1):37-41. PubMed ID: 2322989 [TBL] [Abstract][Full Text] [Related]
28. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
29. Intracellular glutathione levels in human colon cancer cells naturally resistant to cross-linking agents. Ozawa S; Iwata K; Kubodera A; Inaba M J Pharmacobiodyn; 1989 Jul; 12(7):378-83. PubMed ID: 2593079 [TBL] [Abstract][Full Text] [Related]
30. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Lai SL; Hwang J; Perng RP; Whang-Peng J Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042 [TBL] [Abstract][Full Text] [Related]
31. Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line. Chen G; Hutter KJ; Bullerdiek J; Zeller WJ J Cancer Res Clin Oncol; 1991; 117(6):539-42. PubMed ID: 1744159 [TBL] [Abstract][Full Text] [Related]
32. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin. Chen G; Zeller WJ Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216 [TBL] [Abstract][Full Text] [Related]
33. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Lai GM; Ozols RF; Young RC; Hamilton TC J Natl Cancer Inst; 1989 Apr; 81(7):535-9. PubMed ID: 2493524 [TBL] [Abstract][Full Text] [Related]
34. Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin. Bernges F; Zeller WJ J Cancer Res Clin Oncol; 1996; 122(11):665-70. PubMed ID: 8898976 [TBL] [Abstract][Full Text] [Related]
35. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Andrews PA; Murphy MP; Howell SB Cancer Res; 1985 Dec; 45(12 Pt 1):6250-3. PubMed ID: 4063975 [TBL] [Abstract][Full Text] [Related]
37. Glutathione related enzymes in cis-diamminedichloroplatinum (II)-sensitive and-resistant human ovarian carcinoma cells. Oguchi H; Kikkawa F; Kojima M; Maeda O; Mizuno K; Suganuma N; Kawai M; Tomoda Y Anticancer Res; 1994; 14(1A):193-200. PubMed ID: 7909418 [TBL] [Abstract][Full Text] [Related]
38. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Andrews PA; Murphy MP; Howell SB Cancer Chemother Pharmacol; 1987; 19(2):149-54. PubMed ID: 3568272 [TBL] [Abstract][Full Text] [Related]
39. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765 [TBL] [Abstract][Full Text] [Related]
40. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines. Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]